Corrective Phases R...
Health Care: Drugs
Cell Therapeutics Inc. (CTIC: NASDAQ)
$0.86 -0.03 | -3.86%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -62.36M | -82.64M | -95.40M | -180.03M |
| Operating Gains/Losses | 0.00 | -194.00K | -17.62M | -9.45M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 991.00K | -895.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 291.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -310.00K | -1.40M | -1.48M | 2.79M |
| (Decrease) Increase In Other Current Liabilities | -211.00K | -3.79M | -10.75M | 779.00K |
| (Increase) Decrease In Other Working Capital | -3.90M | -360.00K | 6.98M | 73.82M |
| Other Non-Cash Items | 3.35M | 22.90M | 29.97M | 25.82M |
| Net Cash From Continuing Operations | -60.46M | -63.13M | -88.19M | -80.21M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -60.46M | -63.13M | -88.19M | -80.21M |
| Sale of Property, Plant & Equipment | 31.00K | 85.00K | 887.00K | 3.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 600.00K | 12.62M |
| Purchases of Property, Plant & Equipment | -2.70M | -2.01M | -1.48M | -1.91M |
| Acquisitions | 0.00 | 0.00 | 21.83M | 4.41M |
| Purchases of Short-Term Investments | 0.00 | -350.00K | 0.00 | -10.72M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.67M | -2.28M | 21.84M | 4.41M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 213.97M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 108.59M | 89.16M | 114.43M | 5.08M |
| Repayment of Long-Term Debt | -21.16M | -38.52M | -154.00K | -125.96M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | -473.00K |
| Payment of Cash Dividends | 0.00 | 0.00 | -3.11M | -18.86M |
| Other Financing Charges, Net | -424.00K | -928.00K | -16.39M | -39.00K |
| Net Cash From Financing Activities | 87.00M | 49.72M | 94.78M | 73.73M |
| Effect of Exchange Rate Changes | 529.00K | 520.00K | -690.00K | -3.65M |
| Net Change in Cash & Cash Equivalents | 24.40M | -15.16M | 27.74M | -5.73M |
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserImagine!
- Userfrankiesun09@gmail.com
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
- Userbiotech121
- UserJswaim
- UserSLITraders
Latest CTIC Headlines from TheStreet
- Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course 04.19.12 | 03:04 pm
- The 5 Dumbest Things on Wall Street This Week: Feb. 3 02.03.12 | 06:02 am
- The 5 Dumbest Things on Wall Street: Feb. 3
02.03.12 | 05:02 am - Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 01.30.12 | 05:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- 22 Hot Drugs Facing FDA Approval in 2012 11.29.11 | 08:11 am
- 10 Best Mutual Funds for 2012 11.16.11 | 07:11 am
Press Releases for CTIC
- Cell Therapeutics Completes Acquisition Of Pacritinib A Highly Selective JAK2 Inhibitor - PR Newswire 06.04.12 | 01:06 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 06.01.12 | 04:06 pm
- Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published In The Lancet Oncology - PR Newswire 05.31.12 | 01:05 am
- Cell Therapeutics' Aequus BioPharma Validates Its Proprietary GlycoPolymer Technology For The Extension Of The Half-life Of Therapeutic Protein Drugs - PR Newswire 05.30.12 | 01:05 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 05.29.12 | 04:05 pm
- Cell Therapeutics Announces Institutional Investor To Purchase $40 Million Of Convertible Preferred Stock And Warrants To Purchase Common Stock - PR Newswire 05.29.12 | 03:05 am
- Cell Therapeutics' Pixuvri® Approved In European Union As Monotherapy To Treat Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas - PR Newswire 05.10.12 | 02:05 pm
- Cell Therapeutics Enters Into Agreement To Acquire Pacritinib, A Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate For Myelofibrosis - PR Newswire 04.19.12 | 01:04 am
- University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO⢠(Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer - PR Newswire 03.27.12 | 01:03 am
- European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri⢠- PR Newswire 02.17.12 | 07:02 am
Partner Headlines for CTIC
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Cell Therapeutics Plummeting on NDA Withdrawl - Benzinga 01.30.12 | 09:01 am
- US Panel to Review CTIC's Pixantrone - Analyst Blog - Zacks 01.04.12 | 10:01 am
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal - NASDAQ 12.09.11 | 05:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- CTIC Loss Widens, Resubmits NDA - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Cell Therapeutics Efforts Validated - Analyst Blog - Zacks 10.07.11 | 04:10 pm
- Morning Market Movers - Benzinga 08.31.11 | 09:08 am
